Gastroesophageal Junction Adenocarcinoma
Showing NaN - NaN of 7
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Worldwide (tucatinib,
Active, not recruiting
- Gastric Adenocarcinoma
- +2 more
- tucatinib
- +5 more
-
Birmingham, Alabama
- +47 more
Oct 27, 2022
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8,
Recruiting
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- +27 more
- Carboplatin
- +4 more
-
Anchorage, Alaska
- +469 more
Aug 24, 2022
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Ramucirumab, Capecitabine,
Completed
- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Ramucirumab
- +4 more
-
Fayetteville, Arkansas
- +134 more
Jul 29, 2021
Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Boston, New York, Nashville
Completed
- Advanced Cancer
- +5 more
-
Boston, Massachusetts
- +3 more
Nov 24, 2020
Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer Trial in Boston, Newton (FOLFOX/ nal-IRI, Paclitaxel,
Not yet recruiting
- Gastroesophageal Junction Adenocarcinoma
- Esophagogastric Cancer
- FOLFOX/ nal-IRI
- +3 more
-
Boston, Massachusetts
- +2 more
Nov 30, 2020
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Ramucirumab, Paclitaxel)
Completed
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
-
Duarte, California
- +51 more
Jun 10, 2020
NSCLC, Carcinoma, Renal Cell, Breast Tumors Trial in United States (SGN-2FF, pembrolizumab)
Terminated
- Carcinoma, Non-Small-Cell Lung
- +7 more
-
Birmingham, Alabama
- +10 more
Jul 17, 2019